AbInitio Bio
YC X26Boston, US · Founded 2026 · 2 employees · 1 known investors
Find your way into AbInitio Bio
1,595 people in our graph share verified history with the AbInitio Bio team — schools, employers, funds. One of them is your warm intro.
Deep Nisharunlockedknows Nisha Gopal · together at Stanford University (overlapped)
×5knows the team · via Stanford University
×4knows the team · via Broad Institute of MIT and Harvard
knows the team · via Massachusetts Institute of Technology
knows the team · via UCLA
AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.
Founders & leadership· Y Combinator alumni (X26)
AbInitio Bio was founded in 2026 by Daniel Mukasa and Nisha Gopal.
DM
Daniel Mukasain𝕏FounderDaniel Mukasa holds a PhD in Applied Physics and Materials Science from Caltech and completed postdoctoral work at MIT on AI and drug discovery applications. He previously worked as an AI/ML intern at Merck on antibody therapeutic design, and is now founder and CEO of AbInitio Bio.
NG
Nisha GopalinCo-Founder & CSONisha Gopal holds a PhD in biochemistry from Stanford and brings 14 years of research experience, including prior work as a research scientist at the Broad Institute. She is founder and Chief Scientific Officer of AbInitio Bio.
Investors · 1
Competitors · 5
by search overlap
bio8 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Avidbio6 shared keywordsAvid Bio provides development and manufacturing services for biologics programs, offering integrated support from early-stage development through commercialization. The company partners with pharmaceutical and biotech teams as a contract development and manufacturing organization (CDMO) with US-based operations.
Actio Biosciences, Inc.4 shared keywordsActio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions. It focuses on identifying dysregulated gene activity and designing therapies to restore balance and address the root causes of disease.
iBio4 shared keywordsiBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.
Infinant Health3 shared keywordsInfinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants. The company operates in the infant health and microbiome therapeutics space.
Companies competing with AbInitio Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does AbInitio Bio do?
- AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.
- Who founded AbInitio Bio?
- AbInitio Bio was founded by Daniel Mukasa, Nisha Gopal in 2026.
- Who are AbInitio Bio's investors?
- AbInitio Bio's investors include Y Combinator.
- Where is AbInitio Bio headquartered?
- AbInitio Bio is headquartered in Boston, US.